Not provided
Not provided
Not provided
Not provided
An IDMC validated the premature termination of the study on 19/02/2016 for lack of inclusion, with continuation of the FU initially planned for women included
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cemka-Eval | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate and compare the return to work rate at 12 months
Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first adjuvant chemotherapy regimen]) between the "intervention" group (which has accompanied the career) and the standard group course
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group "intervention" | Experimental | Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops). |
|
| Group "standard" | No Intervention | conventional support |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| personalized coaching | Behavioral | personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate and compare the return to work rate | Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first adjuvant chemotherapy regimen]) between the "intervention" group (which has accompanied the career) and the standard group course | through study completion, an average of 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| describe the conditions of the resumption of work | The study will also allow to describe the conditions of the resumption of work in 12 months for the patients concerned and to compare these conditions between the 2 groups | through study completion, an average of 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| William JACOT | Institut régional du Cancer de Montpellier | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut réginal du Cancer de Montpellier | Montpellier | 34298 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |